A5045303436- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- RNA Interference and Gene Delivery
- Galectins and Cancer Biology
- T-cell and B-cell Immunology
- Porphyrin Metabolism and Disorders
- Glutathione Transferases and Polymorphisms
- Immunodeficiency and Autoimmune Disorders
- Genomics, phytochemicals, and oxidative stress
Ablynx (Belgium)
2014-2021
Ghent University
2008
Abstract Protein scaffolds can provide a promising alternative to antibodies for various biomedical and biotechnological applications, including therapeutics. Here we describe the design development of Alphabody, protein scaffold featuring single-chain antiparallel triple-helix coiled-coil fold. We report affinity-matured Alphabodies with favourable physicochemical properties that specifically neutralize human interleukin (IL)-23, pivotal therapeutic target in autoimmune inflammatory...
Genome analysis of Shewanella oneidensis, a Gram-negative bacterium with an unusual repertoire respiratory and redox capabilities, revealed the presence six glutathione S-transferase-like genes (sogst1–sogst6). Glutathione S-transferases (GSTs; EC 2.5.1.18) are found in all kingdoms life involved phase II detoxification processes by catalyzing nucleophilic attack reduced on diverse electrophilic substrates, thereby decreasing their reactivity. Structure–function studies prokaryotic GST-like...
Abstract We have developed Cell Penetrating Alphabodies (CPABs), a novel and unique therapeutic class of proteins engineered to efficiently enter cells. In vitro, uptake in range tumor non-tumor cell types occurs rapidly with cytosol levels up 1 μM concentration after 2 hours CPAB exposure. Early forms these CPABs suffered from rapid serum clearance, thereby limiting their efficacy vivo amenability drug development. The incorporation an albumin binding region the body protein has allowed...
The therapeutic scope of antibody and nonantibody protein scaffolds is still prohibitively limited against intracellular drug targets. Here, we demonstrate that the Alphabody scaffold can be engineered into a cell-penetrating antagonist induced myeloid leukemia cell differentiation MCL-1, an target in cancer, by grafting critical B-cell lymphoma 2 homology 3 helix MCL-1 onto tagging scaffold's termini with designed cell-penetration polypeptides. Introduction albumin-binding moiety extended...
Abstract The pro-survival protein Myeloid Cell Leukaemia-1 (Mcl-1) plays an essential role in survival of numerous cancers. MCL-1 gene amplifications occur a variety human cancers and overexpression the Mcl-1 is often associated with chemotherapeutic resistance disease relapse. Complix has developed Penetrating Alphabodies (CPAB), novel unique therapeutic class proteins engineered to efficiently enter cells inhibit including Mcl-1. High affinity (ABs) targeting were by combination rational...